Media coverage about Collegium Pharmaceutical (NASDAQ:COLL) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.0124070219543 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

NASDAQ COLL opened at $23.20 on Tuesday. The company has a market capitalization of $768.10, a price-to-earnings ratio of -9.39 and a beta of 0.76. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The business’s quarterly revenue was up 728.4% on a year-over-year basis. equities analysts forecast that Collegium Pharmaceutical will post -0.76 earnings per share for the current year.

COLL has been the subject of a number of research reports. Janney Montgomery Scott set a $26.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, February 6th. Piper Jaffray set a $33.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, January 23rd. TheStreet upgraded Collegium Pharmaceutical from a “d+” rating to a “c” rating in a report on Wednesday, March 7th. Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, BidaskClub upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Wednesday, March 28th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $30.83.

In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the completion of the transaction, the chairman now owns 535,395 shares in the company, valued at approximately $13,390,228.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 25.76% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical (COLL) Receiving Somewhat Positive Press Coverage, Analysis Finds” was published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/04/17/collegium-pharmaceutical-coll-receiving-somewhat-positive-press-coverage-analysis-finds.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.